924653-87-2

Basic information

• Product Name: 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy
• Synonyms: 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy
• CAS NO: 924653-87-2
• Molecular Weight: 602.778
• Mol File: 924653-87-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy(924653-87-2)
• EPA Substance Registry System: 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy(924653-87-2)

Safety Data

• Hazardous Substances Data: 924653-87-2(Hazardous Substances Data)

Upstream product

• 37149-18-1 1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine 
• 145004-89-3 3-<<2'-aminosulfonyl><1,1'-biphenyl-4-yl>-methyl>-5,7-dimethyl-2-ethyl-imidazo<4,5-b>pyridine 

Relevant articles and documents

Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use

The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.